Maridebart Cafraglutide
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SW
Amgen · Phase 3 · Recruiting · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| MariTide Arm 1 | n/r | n/r | n/r | n/r |
| MariTide Arm 2 | n/r | n/r | n/r | n/r |
Not shown
- MariTide Arm 1: endpoint not reported
- MariTide Arm 2: endpoint not reported